UC Davis/NIH NeuroMab Facility

加州大学戴维斯分校/NIH NeuroMab 设施

• 批准号: 9511924
• 负责人: James S Trimmer
• 金额: $ 26.13万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-15 至 2019-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9511924
• 关键词: Address; Adult; Antibodies; Antigens; Area; Base Sequence; Biochemical; Biological Assay; Brain; Brain Diseases; California; Catalogs; Cells; Communities; Contractor; DNA Sequence; Data; Diagnostic Procedure; Disabled Persons; Ensure; Funding; Funding Agency; Future; Generations; Genome; Human; Hybridomas; Immunization; Immunoglobulins; Income; Income Distributions; Institution; Laboratory Research; Licensing; Link; Literature; Membrane Proteins; Methodology; Mining; Mission; Monoclonal Antibodies; Monoclonal Antibody R24; Mus; National Institute of Neurological Disorders and Stroke; Neurosciences; Neurosciences Research; Peer Review; Play; Price; Productivity; Protein Analysis; Protein Biochemistry; Proteins; Protocols documentation; Publications; Reagent; Recombinants; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Running; Savings; Seeds; Source; Specificity; Synthetic Vaccines; Therapeutic; Time; United States National Institutes of Health; Universities; Vial device; Work; aged; base; cost; design; experience; flexibility; gene product; mammalian genome; nervous system disorder; novel; programs; protein function; public health relevance; receptor; research and development

 DESCRIPTION (provided by applicant): The availability of high-quality, reliable and monospecific mouse monoclonal antibodies (mAbs) that have been validated and optimized for use in mammalian brain (i.e. NeuroMabs) is of utmost importance to many areas of neuroscience research. Having such reagents for each of the proteins expressed in the brain is necessary to undertake biochemical and immunohistochemical studies to begin to link the nucleic acid sequence information derived from genome-based approaches to the function of the encoded gene products in the brain. Unfortunately, the lack of antibodies against a particular gene product, or antibodies that lack specificity, can severely handicap an entire subfield of neuroscience research and thereby impede progress towards understanding the mechanisms that underlie neurological disease. The UC Davis/NIH NeuroMab Facility works towards this unmet need in two major ways: by generating NeuroMabs for targets that are deemed high-priority by NIH and by distributing them on a low-cost non-profit basis to the neuroscience research community. Seed funds from UC Davis and various NIH sources allowed for the creation of our Facility in 2005 and, over the past nine years, we have undertaken mAb projects against over 400 brain proteins and generated a catalog of over 370 NeuroMabs. Through our contractor Antibodies Incorporated (AI), we have distributed over 44,500 vials of NeuroMabs at low cost to hundreds of researchers at a multitude of different institutions worldwide and our end users have cited the use of NeuroMabs in over 1500 original research publications. Assuming a conservative for-profit price of $350 per 100 µg vial of purified mAb, an estimate of the NeuroMab non-profit savings to end users and their respective funding agencies is over $12.5 million. We have proven ourselves to be an establishment with a strong track record of important contributions and we wish to continue serving neuroscience researchers as best as we can. The worthiness of our Facility to the NIH and its mission has been demonstrated time and again through various funding initiatives over the years, most recently from the NIH Director's Transformative R01 Program. In addition, the combined support and cooperation of the NIH, the Regents of the University of California and AI have enabled us since 2011 to collect program income from the distribution of NeuroMabs to support future Facility self-sufficiency and new mAb research and development. However, the combination of the Transformative R01 funds and the accumulated program income is insufficient to hold onto our experienced senior staff, to keep the Facility running at its present-day level of productivity and to continue doing projects of high priority to NINDS. Maintaining strong support from NIH through additional R24 funding would be instrumental to retaining our valuable human and technological resources, preserving our current UC Davis infrastructure and keeping intact our exceptional protection from royalty and licensing surcharges that would unnecessarily raise the prices of NeuroMabs for our end users.

 描述（由适用提供）：高质量，可靠和单特异性小鼠单克隆抗体（MAB）的可用性，这些抗体（mAb）已经过验证和优化，可用于哺乳动物大脑（即神经毛单抗），对于许多神经科学研究的许多领域至关重要。对于在大脑中表达的每种蛋白质的试剂对于进行生化和免疫组织化学研究是必要的，以开始将基于基因组的方法得出的核酸序列信息与大脑中编码的基因产物的功能联系起来。不幸的是，缺乏针对特定基因产物的抗体或缺乏特异性的抗体，可以严重残障神经科学研究的整个子领域，从而阻碍理解神经系统疾病的机制的进展。 UC Davis/NIH神经瘤设施以两种主要方式致力于这种未满足的需求：通过为NIH认为高优先级的靶标并通过低成本非营​​利性分配神经科学研究界的靶标的神经瘤。来自加州大学戴维斯分校的种子基金和各种NIH来源允许在2005年创建我们的设施，在过去的九年中，我们已经针对400多个脑蛋白进行了MAB项目，并产生了超过370个神经瘤的目录。通过我们的承包商抗体（AI），我们在全球众多不同机构的数百名研究人员中以低成本分发了44,500瓶神经瘤，我们的最终用户引用了1500多个原始研究出版物中神经瘤的使用。假设保守的营利性价格为每100 µg纯化的MAB $ 350，则对最终用户及其各自的资助机构的Neuromab非营利性节省的估计值超过1,250万美元。我们已经证明自己是一个具有重要贡献的良好记录的机构，我们希望继续为神经科学研究人员提供最好的服务。多年来，我们的设施对NIH的价值及其使命的价值一次又一次地通过了各种资金计划，最近一次来自NIH董事的变革性R01计划。此外，NIH的联合支持与合作，加利福尼亚大学和AI大学的摄政量使我们自2011年以来能够从神经单抗分布中收集计划收入，以支持未来的设施自给自足以及新的MAB研究和开发。但是，变革性R01资金和累积计划收入的结合不足以保留我们经验丰富的高级员工，无法使该设施保持其当今的生产率水平，并继续对Ninds进行高度优先级的项目。通过额外的R24资金来维持NIH的大力支持将有助于保留我们有价值的人力和技术资源，保留我们当前的UC Davis基础设施，并完整地保护我们免受特许权使用费和许可调查的特殊保护，这将不必要地提高我们最终用户的NeuroMabs的价格。